PT Isolated polypeptide with a human transport protein sequence is useful
PT for the diagnosis, prevention and treatment of disorders associated
PT with the immune, reproductive and cardiovascular systems -
XX
PS Claim 2; Page 108-109; 165pp; English.
XX
CC The present invention provides the protein and coding sequences for 43
CC novel human transport proteins (designated TPPTs). These can be used in
CC the diagnosis and treatment of transport, metabolic, neurological,
CC reproductive, cardiovascular and immune disorders, and cell proliferative
CC disorders such as cancer.
XX
SQ Sequence 374 AA;

Query Match 100.0%; Score 1345; DB 22; Length 374;
Best Local Similarity 100.0%; Pred. No. 3.7e-144;
Matches 261; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MESKMGELPLDINIQEPRWDQSTFLGRARHFFTVTDPRNLLLSGAQLEASRNIVQNYRAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MESKMGELPLDINIQEPRWDQSTFLGRARHFFTVTDPRNLLLSGAQLEASRNIVQNYRAG 60

Qy         61 VVTPGITEDQLWRAKYVYDSAFHPDTGEKVVLIGRMSAQVPMNMTITGCMLTFYRKTPTV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 VVTPGITEDQLWRAKYVYDSAFHPDTGEKVVLIGRMSAQVPMNMTITGCMLTFYRKTPTV 120

Qy        121 VFWQWVNQSFNAIVNYSNRSGDTPITVRQLGTAYVSATTGAVATALGLKSLTKHLPPLVG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 VFWQWVNQSFNAIVNYSNRSGDTPITVRQLGTAYVSATTGAVATALGLKSLTKHLPPLVG 180

Qy        181 RFVPFAAVAAANCINIPLMRQRELQVGIPVADEAGQRLGYSVTAAKQGIFQVVISRICMA 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 RFVPFAAVAAANCINIPLMRQRELQVGIPVADEAGQRLGYSVTAAKQGIFQVVISRICMA 240

Qy        241 IPAMAIPPLIMDTLEKKDFLK 261
              |||||||||||||||||||||
Db        241 IPAMAIPPLIMDTLEKKDFLK 261
```

RESULT 7
AAB41589
ID AAB41589 standard; Protein; 251 AA.
XX
AC AAB41589;
XX
DT 08-FEB-2001 (first entry)
XX
DE Human ORFX ORF1353 polypeptide sequence SEQ ID NO:2706.
XX
KW Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;
KW vulnerary; antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
KW anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;
KW immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
KW hypotensive; dermatological; immunosuppressive; antiinflammatory;
KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
KW antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
KW neurodegenerative disorder; osteoarthritis; graft vs host disease;
KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
KW cholesterol ester storage; systemic lupus erythematosus; infection;
KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
KW bone damage; cartilage damage; antiinflammatory disease; coagulation;
KW thrombosis; contraceptive.
XX
OS Homo sapiens.
XX
PN WO200058473-A2.
XX
PD 05-OCT-2000.
XX
PF 31-MAR-2000; 2000WO-US08621.
XX
PR 31-MAR-1999; 99US-0127607.
PR 02-APR-1999; 99US-0127636.
PR 05-APR-1999; 99US-0127728.
PR 30-MAR-2000; 2000US-0540763.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach M;
XX
DR WPI; 2000-602362/57.
DR N-PSDB; AAC75798.
XX
PT Novel nucleic acids and peptides derived from open reading frame X,
PT useful for treating e.g. cancers, proliferative disorders,
PT neurodegenerative disorders and cardiovascular disease -
XX
PS Claim 11; Page 1942-1943; 5507pp; English.
XX
CC AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,
CC which represent the human ORFX open reading frames 1 to 3161. The ORFX
CC sequences have activities such as: cytostatic; hepatotropic; vulnerary;
CC antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
CC osteopathic; anticonvulsant; antiarthritic; immunosuppressant;
CC immunostimulant; cardiant; thrombolytic; coagulant; vasotropic;
CC antidiabetic; hypotensive; dermatological; immunosuppressive;
CC antiinflammatory; antibacterial; antiviral; antifungal; antirheumatic;
CC antithyroid; and antianaemic. The sequences can be used for determining
CC the presence of or predisposition to, or preventing or treating
CC pathological conditions associated with an ORFX-associated disorder. The
CC nucleic acids can be used to express ORFX proteins in gene therapy
CC vectors. The proteins and nucleic acids may be used to treat cancers,
CC proliferative disorders, neurodegenerative disorders, osteoarthritis,
CC graft vs host disease, cardiovascular disease, diabetes mellitus,
CC hypertension, hypothyroidism, cholesterol ester storage, systemic lupus
CC erythematosus, severe combined immunodeficiency (SCID), AIDS, viral,
CC bacterial or fungal infection, malaria, autoimmune disorders, asthma,
CC allergies, aplastic anaemia, burns, wounds, bone and cartilage damage,
CC nocturnal haemoglobinuria, antiinflammatory disease; to enhance
CC coagulation; to inhibit thrombosis; and as a contraceptive.
XX
SQ Sequence 251 AA;

Query Match 94.3%; Score 1269; DB 21; Length 251;
Best Local Similarity 98.0%; Pred. No. 9.2e-136;
Matches 246; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy          1 MESKMGELPLDINIQEPRWDQSTFLGRARHFFTVTDPRNLLLSGAQLEASRNIVQNYRAG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MESKMGELPLDINIQEPRWDQSTFLGRARHFFTVTDPRNLLLSGAQLEASRNIVQNYRAG 60

Qy         61 VVTPGITEDQLWRAKYVYDSAFHPDTGEKVVLIGRMSAQVPMNMTITGCMLTFYRKTPTV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 VVTPGITEDQLWRAKYVYDSAFHPDTGEKVVLIGRMSAQVPMNMTITGCMLTFYRKTPTV 120

Qy        121 VFWQWVNQSFNAIVNYSNRSGDTPITVRQLGTAYVSATTGAVATALGLKSLTKHLPPLVG 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 VFWQWVNQSFNAIVNYSNRSGDTPITVRQLGTAYVSATTGAVATALGLKSLTKHLPPLVG 180

Qy        181 RFVPFAAVAAANCINIPLMRQRELQVGIPVADEAGQRLGYSVTAAKQGIFQVVISRICMA 240
              |||||||||||||||||||||||||||| |||||||:|||||||||||||:||| ||
Db        181 RFVPFAAVAAANCINIPLMRQRELQVGIPVTDEAGQRLGHSVTAAKQGIFQVVVSRIGMA 240

Qy        241 IPAMAIPPLIM 251
              |||||||:||
Db        241 IPAMAIPPVIM 251
```

RESULT 8
ABG20175
ID ABG20175 standard; Protein; 397 AA.
XX
AC ABG20175;
XX
DT 18-FEB-2002 (first entry)